Aysun Adan

7PUBLICATIONS
2CO-AUTHORS
Gene and molecular therapyMolecular targetsMedical infection agents (incl. prions)Aerodynamics (excl. hypersonic aerodynamics)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 20, 2025
Functional combination of resveratrol and midostaurin induces cytotoxicity to overcome acquired midostaurin resistance in FLT3-ITD expressing acute myeloid leukemia cells.

Melisa Tecik, Aysun Adan

|Mar 22, 2025
Concurrent inhibition of FLT3 and sphingosine kinase-1 triggers synergistic cytotoxicity in midostaurin resistant FLT3-ITD positive acute myeloid leukemia cells via blocking FLT3/STAT5A signaling to induce apoptosis.

Melisa Tecik, Aysun Adan

|May 02, 2024
Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors.

Melisa Tecik, Aysun Adan

|Dec 07, 2022
Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches.

Melisa Tecik, Aysun Adan

|Apr 25, 2022
Differential in vitro anti-leukemic activity of resveratrol combined with serine palmitoyltransferase inhibitor myriocin in FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) carrying AML cells.

Nur Şebnem Ersöz, Aysun Adan

|Jan 21, 2022
Resveratrol triggers anti-proliferative and apoptotic effects in FLT3-ITD-positive acute myeloid leukemia cells via inhibiting ceramide catabolism enzymes.

Nur Şebnem Ersöz, Aysun Adan

Pageof 2

Frequent Collaborators

4 joint publications

Melisa Tecik

2 joint publications

Nur Şebnem Ersöz